Calamos Advisors LLC Lowers Stock Position in Amgen, Inc. (NASDAQ:AMGN)
Calamos Advisors LLC decreased its position in Amgen, Inc. (NASDAQ:AMGN) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 159,397 shares of the medical research company’s stock after selling 1,241 shares during the period. Calamos Advisors LLC’s holdings in Amgen were worth $38,426,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pictet Asset Management Ltd. grew its holdings in Amgen by 20.1% in the second quarter. Pictet Asset Management Ltd. now owns 1,299,390 shares of the medical research company’s stock valued at $239,452,000 after purchasing an additional 217,590 shares during the period. Lido Advisors LLC lifted its position in shares of Amgen by 7.1% during the 2nd quarter. Lido Advisors LLC now owns 5,115 shares of the medical research company’s stock valued at $942,000 after buying an additional 337 shares in the last quarter. ETF Managers Group LLC grew its stake in Amgen by 139.0% in the 2nd quarter. ETF Managers Group LLC now owns 11,235 shares of the medical research company’s stock valued at $2,067,000 after acquiring an additional 6,535 shares during the period. Private Advisor Group LLC grew its stake in Amgen by 4.0% in the 2nd quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock valued at $7,093,000 after acquiring an additional 1,494 shares during the period. Finally, QCI Asset Management Inc. NY increased its holdings in Amgen by 7.4% in the 2nd quarter. QCI Asset Management Inc. NY now owns 2,692 shares of the medical research company’s stock worth $496,000 after acquiring an additional 185 shares in the last quarter. 76.58% of the stock is owned by institutional investors.
NASDAQ AMGN traded up $1.36 on Wednesday, reaching $241.36. 641,916 shares of the company were exchanged, compared to its average volume of 1,877,842. The business’s fifty day moving average price is $238.17 and its 200 day moving average price is $208.52. The stock has a market capitalization of $141.57 billion, a P/E ratio of 16.76, a price-to-earnings-growth ratio of 2.07 and a beta of 1.11. The company has a current ratio of 2.89, a quick ratio of 2.59 and a debt-to-equity ratio of 2.54. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $244.99.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be issued a $1.60 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 annualized dividend and a dividend yield of 2.65%. The ex-dividend date of this dividend is Thursday, February 13th. Amgen’s payout ratio is presently 40.28%.
A number of research firms have weighed in on AMGN. Argus upped their price objective on shares of Amgen from $240.00 to $265.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Sanford C. Bernstein began coverage on shares of Amgen in a research note on Monday, October 14th. They set an “outperform” rating for the company. Cowen upped their price target on shares of Amgen from $253.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. Morgan Stanley assumed coverage on shares of Amgen in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $280.00 price target on the stock. Finally, Royal Bank of Canada reiterated a “hold” rating on shares of Amgen in a report on Monday, September 30th. Eleven analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $235.39.
In other news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total transaction of $91,566.25. Following the transaction, the director now directly owns 5,413 shares in the company, valued at $1,166,230.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jonathan P. Graham sold 9,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total transaction of $2,074,860.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,162 shares of company stock valued at $4,214,030. Insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.